Drug developer Mylan Inc. said Tuesday it received Food and Drug Administration approval for a generic version of GlaxoSmithKline PLC's smoking cessation treatment Zyban.
Zyban had sales of about $9.7 million in 2009, the company said, citing figures from the research firm IMS Health.
Shares of Mylan fell 56 cents, or 2.5 percent, to $21.47 in morning trading.